Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12098-025-05717-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Central Neurophysiological Alterations in Dystrophic mdx Mice Correlate With Reduced Hippocampal Levels of the Endogenous NMDA Receptor Ligand D-Aspartate.
J Neurochem
September 2025
Department of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Rome, Italy.
Patients with Duchenne muscular dystrophy (DMD) may experience neurobehavioral and cognitive concerns, including psychiatric symptoms, due to the absence of full-length dystrophin (Dp427), frequently accompanied by deficiencies in shorter isoforms. The lack of dystrophin affects neurophysiological processes from the uterine phase, impacting neural circuitry in brain regions such as the prefrontal cortex, hippocampus, and cerebellum. This leads to reduced inhibitory GABAergic transmission and altered hippocampal glutamatergic signaling.
View Article and Find Full Text PDFSensitivity of Different Clinical Outcome Measures in Assessing Adults With Becker Muscular Dystrophy: A 3-Year Natural History Study.
Neurology
October 2025
Department of Neurology, Leiden University Medical Center, the Netherlands.
Background And Objectives: Slow and highly variable disease progression in Becker muscular dystrophy (BMD) stresses the need to develop sensitive outcome measures for clinical trials. We evaluated responsiveness of different outcome measures in adult patients with BMD over 3 years and explored if the sensitivity of outcome measures can be increased by selecting on phenotype or genotype.
Methods: Genetically confirmed patients with BMD were recruited via the Dutch Dystrophinopathy Database.
Continuous Ventilatory Support Without Hospitalization or Tracheotomies: A Retrospective Observational Study of Two Centers' Outcomes for Duchenne Muscular Dystrophy.
Am J Phys Med Rehabil
August 2025
Center for Neuromuscular Disease Child Health and Development, National Hospital Organization, Hokkaido, Medical Center, Japan.
Introduction: Duchenne muscular dystrophy (DMD) management often results in tracheostomies or palliative care deaths.
Methods: Two centers, A in the U.S.
Corticosteroid therapy in Duchenne muscular dystrophy: Management and new insights.
Dev Med Child Neurol
September 2025
Pediatric Neurology Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
[Chinese guidelines on the multidisciplinary management of Duchenne muscular dystrophy].
Zhonghua Nei Ke Za Zhi
September 2025
Duchenne muscular dystrophy (DMD) is an X-linked recessive myopathy caused by mutations in the dystrophin gene, which is divided into presymptomatic, early ambulatory, late ambulatory, early non-ambulatory, and late non-ambulatory stages according to its disease progression. Some patients experience non-progressive cognitive developmental delays in the presymptomatic stage. DMD patients gradually develop osteoporosis, cardiomyopathy, decreased respiratory function, delayed puberty, and gastrointestinal symptoms as the disease progresses.
View Article and Find Full Text PDF